Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study

Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study

Objective To evaluate the cost-effectiveness of risk-stratified hepatocellular carcinoma (HCC) screening in diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD).Design A state-transition model from a healthcare payer perspective on a lifetime horizon.Setting Japan....

Full description

Saved in:

Bibliographic Details
Main Author:	Akiko Kowada
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-11-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/14/11/e080549.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Julia Markowska, et al.
Published: (2024-11-01)

Myokines and Their Potential Protective Role Against Oxidative Stress in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: José Luis Bucarey, et al.
Published: (2024-11-01)

Exploratory Role of Flavonoids on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a South Italian Cohort
by: Caterina Bonfiglio, et al.
Published: (2024-10-01)

Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Xue Zou, et al.
Published: (2024-12-01)

Ergothioneine ameliorates metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) by enhancing autophagy, inhibiting oxidative damage and inflammation
by: Xiaoyu Lv, et al.
Published: (2024-11-01)

Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis
by: Isabel Omaña-Guzmán, et al.
Published: (2024-11-01)

Effect of a Ketogenic Diet on Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Progression: A Randomized Controlled Trial
by: Sakkarin Chirapongsathorn, et al.
Published: (2025-01-01)

A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
by: Jeffrey V. Lazarus, et al.
Published: (2025-01-01)

P-88 rs641738 MBOAT7 POLYMORPHISM AS A PREDICTOR OF FIBROSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
by: Sofia Rocha, et al.
Published: (2024-12-01)

Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
by: Umasankari S., et al.
Published: (2024-12-01)

Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis
by: Wu X, et al.
Published: (2025-02-01)

Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its association with arterial stiffness in adolescents: Results from the EVA4YOU study.
by: Johannes Nairz, et al.
Published: (2024-01-01)

Cold-Pressed <i>Aristotelia chilensis</i> (Mol.) Stuntz Seed Oil Prevents Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) in a High-Fat-Diet-Induced Obesity Murine Model
by: Benjamín Claria, et al.
Published: (2024-11-01)

Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD)
by: Lucy C. Taylor, et al.
Published: (2024-12-01)

Interplay of Oxidative Stress, Gut Microbiota, and Nicotine in Metabolic-Associated Steatotic Liver Disease (MASLD)
by: Irene Mignini, et al.
Published: (2024-12-01)

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01)

A Moderate Intake of Beer Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a High-Fat Diet (HFD)-Induced Mouse Model
by: Andrea Vornoli, et al.
Published: (2024-12-01)

P-87 TRANSCULTURAL ADAPTATION OF THE MEDITERRANEAN DIET TO THE DIETARY HABITS OF EACH GEOGRAPHICAL REGION OF ARGENTINA FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
by: Maria Adela Crosetti, et al.
Published: (2024-12-01)

A narrative review about cognitive impairment in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach
by: Marica Meroni, et al.
Published: (2025-02-01)

Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
by: Felicianna, et al.
Published: (2024-12-01)

Characterization of liver, adipose, and fecal microbiome in obese patients with MASLD: links with disease severity and metabolic dysfunction parameters
by: Katherine J. P. Schwenger, et al.
Published: (2025-01-01)

Obesity and Cancer Screening according to Race and Gender
by: Heather Bittner Fagan, et al.
Published: (2011-01-01)

P-107 CLINICAL SPECTRUM OF METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN PATIENTS WITH ALTERED ANKLE-BRACHIAL INDEX (ABI) AND CARDIOVASCULAR (CV) RISK FACTORS.
by: Diana Karen Tapia Calderón, et al.
Published: (2024-12-01)

An Assessment of the Feasibility, Patient Acceptance, and Performance of Point-of-Care Transient Elastography for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis
by: Taranika Sarkar Das, et al.
Published: (2024-11-01)

Early-life antibiotic exposure aggravate the metabolic dysfunction-associated steatotic liver disease associated hepatocellular carcinoma
by: Panpan Tian, et al.
Published: (2024-11-01)

High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction
by: Seong-Uk Baek, et al.
Published: (2024-11-01)

P- 15 GENETIC AND CLINICAL CHARACTERISTICS IN LEAN MASLD PATIENTS WITH AND WITHOUT CIRRHOSIS IN LATINOAMERICAN POPULATION
by: Karina Sato Espinoza, et al.
Published: (2024-12-01)

Immunity revealed: Stratifying hepatocellular carcinoma for precision immunotherapy
by: Konstantinos Arvanitakis, et al.
Published: (2025-03-01)

Holy Basil (<i>Ocimum sanctum</i> L.) Flower and Fenofibrate Improve Lipid Profiles in Rats with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): The Role of Choline Metabolism
by: Siraphat Taesuwan, et al.
Published: (2024-12-01)

OP-7 Further exploration of differences between lean and non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) in Latino subjects: PNPLA3 frequency and lipidomic profiles
by: MARIA AYALA VALVERDE, et al.
Published: (2024-12-01)

P-19 ASSOCIATION OF TM6SF2 GENE POLYMORPHISMS WITH CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A HISPANIC ADULT POPULATION
by: LUISA FERNANDA SANTOS CUERVO, et al.
Published: (2024-12-01)

Metabolic dysfunction-associated steatotic liver disease
by: Chieh Chen, et al.
Published: (2024-12-01)

Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females
by: Xiaoning Gan, et al.
Published: (2024-12-01)

Microbiota and metabolic dysfunction associated with steatotic liver disease
by: Q. Zhu, et al.
Published: (2024-09-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Progressive Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) from a Young Age Due to a Rare Genetic Disorder, Familial Partial Lipodystrophy: A Case Report and Review of the Literature
by: Elena Vorona, et al.
Published: (2024-12-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People Living With HIV Attending Centre of Excellence in HIV Care at a Tertiary Level Teaching Hospital in North India—A Pilot Study
by: Ragini Ram, et al.
Published: (2025-01-01)

Effectiveness of flaxseed consumption and fasting mimicking diet on anthropometric measures, biochemical parameters, and hepatic features in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a randomized controlled clinical trial
by: Navideh Khodadadi, et al.
Published: (2024-11-01)

The development of a food-group, tree classification method and its use in exploring dietary associations with metabolic dysfunction-associated Steatotic liver disease (MASLD) and other health-related outcomes in a UK population
by: Amina A. Alawadi, et al.
Published: (2025-03-01)

CT and MR Imaging of Hepatocellular Carcinoma and Liver Cirrhosis
by: Masahiro Okada, et al.
Published: (2024-11-01)